HRP20110047T1 - Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina - Google Patents

Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina Download PDF

Info

Publication number
HRP20110047T1
HRP20110047T1 HR20110047T HRP20110047T HRP20110047T1 HR P20110047 T1 HRP20110047 T1 HR P20110047T1 HR 20110047 T HR20110047 T HR 20110047T HR P20110047 T HRP20110047 T HR P20110047T HR P20110047 T1 HRP20110047 T1 HR P20110047T1
Authority
HR
Croatia
Prior art keywords
amino
compound
formula
thiazolo
thio
Prior art date
Application number
HR20110047T
Other languages
English (en)
Croatian (hr)
Inventor
Nordvall Gunnar
Ray Colin
Rein Tobias
Sohn Daniel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20110047T1 publication Critical patent/HRP20110047T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20110047T 2005-04-06 2006-04-03 Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina HRP20110047T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06
PCT/SE2006/000399 WO2006107258A1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Publications (1)

Publication Number Publication Date
HRP20110047T1 true HRP20110047T1 (hr) 2011-03-31

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110047T HRP20110047T1 (hr) 2005-04-06 2006-04-03 Novi derivati 5-supstituiranog 7-amino-[1,3]tiazolo[4,5-d]pirimidina

Country Status (30)

Country Link
US (2) US7947693B2 (enExample)
EP (1) EP1869056B1 (enExample)
JP (1) JP5165553B2 (enExample)
KR (1) KR101335055B1 (enExample)
CN (1) CN101193897B (enExample)
AR (1) AR055890A1 (enExample)
AT (1) ATE487727T1 (enExample)
AU (1) AU2006231836B2 (enExample)
BR (1) BRPI0609738A2 (enExample)
CA (1) CA2604017C (enExample)
CY (1) CY1111316T1 (enExample)
DE (1) DE602006018124D1 (enExample)
DK (1) DK1869056T3 (enExample)
ES (1) ES2354450T3 (enExample)
HR (1) HRP20110047T1 (enExample)
IL (1) IL185912A0 (enExample)
MX (1) MX2007012060A (enExample)
NO (1) NO20075603L (enExample)
NZ (1) NZ561460A (enExample)
PL (1) PL1869056T3 (enExample)
PT (1) PT1869056E (enExample)
RS (1) RS51581B (enExample)
RU (1) RU2419623C2 (enExample)
SA (1) SA06270072B1 (enExample)
SI (1) SI1869056T1 (enExample)
TW (1) TW200714605A (enExample)
UA (1) UA90707C2 (enExample)
UY (1) UY29454A1 (enExample)
WO (1) WO2006107258A1 (enExample)
ZA (1) ZA200708187B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
CN101522693B (zh) 2006-09-29 2012-01-04 阿斯利康(瑞典)有限公司 5，7-二取代的[1，3]噻唑并[4，5-d]嘧啶-2(3h)-胺衍生物和它们在治疗中的用途
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
WO2014142056A1 (ja) 2013-03-12 2014-09-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン－３－イル酢酸誘導体の塩およびその結晶
EP3049086A4 (en) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20180222922A1 (en) * 2015-06-08 2018-08-09 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
PE20251587A1 (es) 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1
WO2025219939A1 (en) 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219947A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Thio-substituted 1,3,5-triazine cx3cr1 modulators
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (enExample) * 1955-01-03
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
DK0891978T3 (da) * 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
WO1999051608A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
CA2330619A1 (en) 1998-05-01 1999-11-11 Eli Lilly And Company N1-modified glycopeptides
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
SE0004110L (sv) * 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
EP1589901A4 (en) * 2002-12-20 2006-08-09 Generipharm Inc INTRAKUTANE INJECTION
WO2005033115A1 (en) * 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
IL185912A0 (en) 2008-01-06
UY29454A1 (es) 2006-11-30
UA90707C2 (en) 2010-05-25
EP1869056A4 (en) 2010-02-17
EP1869056A1 (en) 2007-12-26
PL1869056T3 (pl) 2011-04-29
US20080214578A1 (en) 2008-09-04
MX2007012060A (es) 2007-12-13
US9440992B2 (en) 2016-09-13
ATE487727T1 (de) 2010-11-15
US20110092519A1 (en) 2011-04-21
AU2006231836B2 (en) 2010-07-15
JP5165553B2 (ja) 2013-03-21
BRPI0609738A2 (pt) 2011-10-18
ES2354450T3 (es) 2011-03-15
KR101335055B1 (ko) 2013-12-02
PT1869056E (pt) 2011-01-13
CN101193897B (zh) 2010-12-01
JP2008535835A (ja) 2008-09-04
DE602006018124D1 (de) 2010-12-23
DK1869056T3 (da) 2011-02-07
RU2007140551A (ru) 2009-05-20
CY1111316T1 (el) 2015-08-05
TW200714605A (en) 2007-04-16
CN101193897A (zh) 2008-06-04
ZA200708187B (en) 2008-11-26
SI1869056T1 (sl) 2011-02-28
KR20080004483A (ko) 2008-01-09
US7947693B2 (en) 2011-05-24
RU2419623C2 (ru) 2011-05-27
HK1118556A1 (en) 2009-02-13
NO20075603L (no) 2008-01-04
EP1869056B1 (en) 2010-11-10
SA06270072B1 (ar) 2009-02-07
AR055890A1 (es) 2007-09-12
CA2604017C (en) 2012-03-06
WO2006107258A1 (en) 2006-10-12
AU2006231836A1 (en) 2006-10-12
CA2604017A1 (en) 2006-10-12
NZ561460A (en) 2010-12-24
RS51581B (sr) 2011-08-31

Similar Documents

Publication Publication Date Title
RU2007140551A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 5-ЗАМЕЩЕННОГО 7-АМИНО-[1,3] ТИАЗОЛА [4,5-d] ПИРИМИДИНА
CA2723207C (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
JP2008535835A5 (enExample)
RU2328494C2 (ru) Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло[2.2.1]гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина
JOP20190257A1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
RU2013138717A (ru) Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе
HRP20050708A2 (en) Piperidine-benzenesulfonamide derivatives
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
RU2009120229A (ru) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
KR950701323A (ko) 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)
CA2758474A1 (en) Novel p2x7r antagonists and their use
RU2007140552A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 5, 7-ДИЗАМЕЩЕННОГО [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3H)-ОНА
RU2014126341A (ru) СОЕДИНЕНИЯ ТИЕНИЛ[3, 2-d]ПИРИМИДИН-4-ОН, СПОСОБ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
BRPI0519287A2 (pt) derivados de amida
RU2009103300A (ru) Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии
EA202091641A1 (ru) 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
AU2010217615A1 (en) Uses of NK receptor antagonists
BRPI0517412A (pt) derivados de benzodiazepina substituìdos
WO2006026204A3 (en) Novel gamma-lactams as beta-secretase inhibitors
RU2008102155A (ru) ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, ЛЕКАРСТВЕННАЯ СУБСТАНЦИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
ES2322046T3 (es) 6,7-dihidro-5h-pirazolo-(1,2a)pirazol-1-onas que controlan citoquinas inflamatorias.
PT1368358E (pt) Derivados de isoxazolina como anti-depressivos
EA201992341A1 (ru) Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
CN102906085A (zh) 2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基-磺酰胺衍生物
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents